Primary endpoint was not achieved Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX),... Read More

EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 Completed $25.5 Million Private Placement Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally... Read More

Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (the “Company” or “Evelo”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis... Read More

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”)... Read More

EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that its Board of Directors has approved a 1-for-20 reverse stock... Read More

Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint Company will focus on development of extracellular vesicles (EVs) First EV candidate, EDP2939, in Phase 2 moderate psoriasis study fully enrolled; data anticipated in early Q4 2023 Management to host conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc.... Read More

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022. “We continued to progress on our SINTAX... Read More

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial... Read More

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7,... Read More

Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated EDP2939 Phase 2 data in psoriasis anticipated in 2H 2023 CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally... Read More

Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed Clear path to registration trials for EDP1815 in psoriasis based on recently completed interactions with FDA, EMA and MHRA Dosing commenced in clinical study with first extracellular vesicle (EV) product candidate EDP2939 in January; Phase 2 data in psoriasis anticipated in... Read More

Horizon Platform Originates $114 Million of New Loans in Q4, Including $104 Million of New Loans for HRZN RZN Grows Loan Portfolio by $262 Million in 2022 Horizon Platform Ends 2022 with Committed Backlog of $255 Million , Including $220 Million in HRZN Commitments FARMINGTON, Conn. , Jan. 11, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance... Read More

CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreement with Horizon Technology Finance Corporation (Horizon) (Nasdaq: HRZN), a leading specialty finance company that provides capital... Read More

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad anti-inflammatory effects of EDP1815, the Company’s lead product candidate in inflammation, in a Phase 2 clinical trial in psoriasis. The data were presented in a poster at the 2022 EADV... Read More

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that on September 1, 2022, Marella Thorell commenced her services as Evelo’s Chief Financial Officer. In connection with the commencement of Ms. Thorell’s employment, the Company issued to Ms. Thorell an option to purchase 440,000... Read More

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Health Care Conference on Tuesday, September 13th, 2022 at 12:20 p.m. ET. A live audio webcast of the panel will be available under “News and... Read More

Simba Gill to transition to Chair of the Board of Directors Lord Ara Darzi will become Lead Independent Director Board has retained Spencer Stuart for Chief Executive Officer search Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced the succession plan for Simba Gill, Ph.D., to... Read More

Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 Phase 2 data for EDP2939 in psoriasis expected in 2H 2023 Management will host conference call at 7:30 a.m. ET Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered... Read More

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 7:30 a.m. ET on Thursday, August 11, 2022, to report its second quarter 2022 financial results. To access the live conference call, please dial (800) 715-9871 (US & Canada)... Read More

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced the appointment of Marella Thorell as Chief Financial Officer (CFO), effective September 1, 2022. Ms. Thorell brings more than 25 years of finance and operations experience, having successfully led multiple M&A, licensing, and... Read More

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 54,246,358 shares of common stock (the “Shares”) at a purchase price of $1.46 per share, resulting in gross proceeds of $79.2 million. The offering is being led by... Read More

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2022. “This quarter we reported positive data for EDP1815 in psoriasis in three key areas: effects on systemic inflammatory cytokine markers; depth and duration of response at 6-month follow-up post dosing; and... Read More

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals, and Tassos Gianakakos, the longtime former CEO of MyoKardia, have joined Evelo as strategic advisors. “We are thrilled to welcome both John and Tassos as strategic advisors to Evelo,” said... Read More

Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022 Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023 Faster release capsule cohort to be added to on-going Phase 2 trial of EDP1815 in atopic dermatitis; data expected 1H 2023 Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality... Read More

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Jose-Carlos Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of Directors. “We are delighted to welcome Jose-Carlos back to our Board. He is one of the world's preeminent drug discovery and immunology leaders, and has vast experience across... Read More